IL308836A - Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses - Google Patents
Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and UsesInfo
- Publication number
- IL308836A IL308836A IL308836A IL30883623A IL308836A IL 308836 A IL308836 A IL 308836A IL 308836 A IL308836 A IL 308836A IL 30883623 A IL30883623 A IL 30883623A IL 308836 A IL308836 A IL 308836A
- Authority
- IL
- Israel
- Prior art keywords
- baev
- truncated
- particles containing
- related methods
- lipid particles
- Prior art date
Links
- 101710121417 Envelope glycoprotein Proteins 0.000 title 1
- 241001504519 Papio ursinus Species 0.000 title 1
- 102100021696 Syncytin-1 Human genes 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 241001430294 unidentified retrovirus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194880P | 2021-05-28 | 2021-05-28 | |
| PCT/US2022/031459 WO2022251712A1 (en) | 2021-05-28 | 2022-05-27 | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308836A true IL308836A (en) | 2024-01-01 |
Family
ID=82851603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308836A IL308836A (en) | 2021-05-28 | 2022-05-27 | Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240254168A1 (enExample) |
| EP (1) | EP4347620A1 (enExample) |
| JP (1) | JP2024521811A (enExample) |
| CN (1) | CN117642420A (enExample) |
| AU (1) | AU2022280957A1 (enExample) |
| CA (1) | CA3219487A1 (enExample) |
| IL (1) | IL308836A (enExample) |
| WO (1) | WO2022251712A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| JP2024532963A (ja) | 2021-04-08 | 2024-09-11 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８特異的抗体コンストラクト及びその組成物 |
| CN113608287B (zh) * | 2021-08-06 | 2023-06-02 | 暨南大学 | 一种微透镜及其应用 |
| US20250082777A1 (en) * | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4602174A1 (en) * | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024254346A1 (en) * | 2023-06-07 | 2024-12-12 | The Broad Institute, Inc. | Engineered viral like particles (evlps) for the selective transduction of target cells |
| WO2024259051A1 (en) * | 2023-06-14 | 2024-12-19 | The Children's Medical Center Corporation | Systems and methods for modifying a polynucleotide |
| CN119264228B (zh) * | 2023-07-04 | 2025-11-25 | 清华大学 | 一种具有广泛细胞嗜性和高效感染效率的包膜蛋白及其应用 |
| TW202540399A (zh) * | 2023-11-14 | 2025-10-16 | 中央研究院 | 用於有效包裹病毒顆粒之經修改的細胞株 |
| CN119020418B (zh) * | 2024-08-17 | 2025-06-13 | 广东君厚生物医药有限公司 | BaEV逆转录病毒载体的包装方法及其包装细胞系 |
| CN122012416A (zh) * | 2026-04-14 | 2026-05-12 | 山东丽山生物科技有限公司 | 一种提高慢病毒滴度的方法 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| WO1999032646A1 (en) | 1997-12-22 | 1999-07-01 | Oxford Biomedica (Uk) Limited | Equine infectious anaemia virus (eiav) based |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| WO2011058052A1 (en) | 2009-11-13 | 2011-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Direct protein delivery with engineered microvesicles |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| US9249426B2 (en) * | 2011-09-29 | 2016-02-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lentiviral vectors pseudotyped with mutant BaEV glycoproteins |
| WO2013148327A1 (en) | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Nipah virus envelope psuedotyped lentiviruses and methods of their use |
| EP3415627A1 (en) | 2012-11-13 | 2018-12-19 | Codiak BioSciences, Inc. | Delivery of therapeutic agent |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| WO2016077639A2 (en) | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| WO2017005923A1 (en) * | 2015-07-09 | 2017-01-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lentiviral vector expressing membrane-anchored or secreted antibody |
| US20180291080A1 (en) | 2015-09-28 | 2018-10-11 | Trustees Of Dartmouth College | Chimeric antigen receptor, regulatory cells and methods of use |
| EP3858388B1 (en) | 2015-09-28 | 2024-07-03 | Regents of the University of Minnesota | Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd |
| JP7059179B2 (ja) | 2015-10-20 | 2022-04-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 遺伝子操作のための方法及び製品 |
| US20170151287A1 (en) | 2015-11-30 | 2017-06-01 | Flagship Ventures Management, Inc. | Methods and compositions of chondrisomes |
| SG10202008883SA (en) | 2016-03-15 | 2020-10-29 | Codiak Biosciences Inc | Therapeutic membrane vesicles |
| US11325948B2 (en) * | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| US11576872B2 (en) | 2017-05-08 | 2023-02-14 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| CN111328290A (zh) | 2017-06-26 | 2020-06-23 | 博德研究所 | 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法 |
| WO2019005886A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
| EP3720502A4 (en) | 2017-12-07 | 2022-01-19 | Flagship Pioneering Innovations V, Inc. | CYTOBIOLOGICS AND THERAPEUTIC USES THEREOF |
| EP3728576A4 (en) | 2017-12-22 | 2021-11-24 | The Broad Institute, Inc. | CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES |
| WO2019126762A2 (en) | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| US20230193242A1 (en) | 2017-12-22 | 2023-06-22 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
| WO2019157319A1 (en) | 2018-02-12 | 2019-08-15 | Flagship Pioneering Innovations V, Inc. | Devices and methods for delivering material into a biological tissue or cell |
| BR112020016570A2 (pt) | 2018-02-17 | 2020-12-15 | Flagship Pioneering Innovations V, Inc. | Composições e métodos para liberação de proteína de membrana |
| CN112367973A (zh) | 2018-05-15 | 2021-02-12 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| US20230048166A1 (en) | 2018-11-14 | 2023-02-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| EP3880179A2 (en) | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| KR20210131991A (ko) | 2018-11-14 | 2021-11-03 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 구획-특이적 카고 전달을 위한 조성물 및 방법 |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| WO2020181193A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenosine methylation |
| WO2020181178A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through thymine alkylation |
| WO2020181202A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to t:a base editing through adenine deamination and oxidation |
| WO2020181195A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenine excision |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US20230235309A1 (en) | 2020-02-05 | 2023-07-27 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CA3193099A1 (en) | 2020-09-24 | 2022-03-31 | David R. Liu | Prime editing guide rnas, compositions thereof, and methods of using the same |
-
2022
- 2022-05-27 IL IL308836A patent/IL308836A/en unknown
- 2022-05-27 JP JP2023573116A patent/JP2024521811A/ja active Pending
- 2022-05-27 CN CN202280050044.8A patent/CN117642420A/zh active Pending
- 2022-05-27 CA CA3219487A patent/CA3219487A1/en active Pending
- 2022-05-27 EP EP22754193.5A patent/EP4347620A1/en active Pending
- 2022-05-27 AU AU2022280957A patent/AU2022280957A1/en not_active Abandoned
- 2022-05-27 WO PCT/US2022/031459 patent/WO2022251712A1/en not_active Ceased
- 2022-05-27 US US18/563,812 patent/US20240254168A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024521811A (ja) | 2024-06-04 |
| US20240254168A1 (en) | 2024-08-01 |
| WO2022251712A1 (en) | 2022-12-01 |
| CN117642420A (zh) | 2024-03-01 |
| AU2022280957A1 (en) | 2023-11-30 |
| AU2022280957A9 (en) | 2023-12-07 |
| CA3219487A1 (en) | 2022-12-01 |
| EP4347620A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU738649B2 (en) | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes | |
| PH12020500579A1 (en) | Mhc class i associated peptides for prevention and treatment of multiple flavi virus | |
| HUP0500319A2 (hu) | Inhalálóeszköz száraz porhoz | |
| PE20071098A1 (es) | Composicion inmugenica que contiene como adyuvantes una saponina y un polisacarido | |
| WO2011150153A3 (en) | Machine bucket | |
| WO2020033527A3 (en) | Recombinant biologically contained filovirus vaccine | |
| MX2019013372A (es) | Composiciones de neisseria meningitidis y sus metodos. | |
| US20190183609A1 (en) | Dental Form Assembly | |
| MA56468A (fr) | Protéines de liaison à l'antigène de carcinome 1 à cellules squameuses de l'oesophage anti-new york (ny-eso-1) et leurs procédés d'utilisation | |
| FR3040984B3 (fr) | Paquet ou sachet a dose unique pouvant etre scelle hermetiquement contenant une capsule ou dosette de cafe biodegradable | |
| MX2023013665A (es) | Polipeptidos del sars-cov-2. | |
| WO2019058133A3 (en) | MHC CLASS I ASSOCIATED PEPTIDES FOR THE PREVENTION AND TREATMENT OF ZIKA VIRUS | |
| Badakar et al. | Fracture resistance of microhybrid composite, nano composite and fibre‐reinforced composite used for incisal edge restoration | |
| EP4190848A4 (en) | Surface-functionalized material and modified material, and preparation methods therefor and use thereof | |
| EP2632942A4 (en) | RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME | |
| Jabbarifar et al. | In vitro comparison of microleakage of a self-etching fissure sealant with a flowable composite resin and a conventional fissure sealant | |
| MY142996A (en) | Intranasal influenza vaccine based on virosomes | |
| FR3074820B1 (fr) | Module de construction pour mur, plancher ou plafond et machine de remplissage pour celui-ci | |
| US20150289830A1 (en) | Barrier envelope for an imaging plate | |
| JP2014102481A (ja) | シート貼付構造体及びシート貼付構造体を用いて保護シートを貼付する貼付方法 | |
| EP2235065A4 (en) | Glycoprotein oligomer of the HIV-1 envelope and its methods of use | |
| US10780109B1 (en) | Method for treating a tooth using selenite | |
| IN2014DN07152A (enExample) | ||
| Abdalla et al. | The Cherenkov Telescope Array: layout, design and performance | |
| SG11202005092PA (en) | Package body for ceramic separation membrane and packaged item |